Life science M&A activity reached $357bn in 2019, report finds
According to new research, M&As within the life science industry reached a high last year and is expected to continue its growth in 2020.
List view / Grid view
News
FDA grants Avatrombopag Orphan Drug Designation for thrombocytopenia
The US FDA has granted avatrombopag (Doptelet) ODD as around 10 percent of US cancer patients per year experience chemotherapy-induced thrombocytopenia (CIT) with no available treatment.
Novartis and NHS partner to improve manufacture of oligonucleotides
A partnership between Novartis and NHS England includes a proposal to investigate processes that can increase the scale and efficacy of oligonucleotide manufacture.
FDA approves Keytruda for patients with high-risk, non-muscle invasive bladder cancer
Keytruda is the first anti-PD-1 monoclonal antibody therapy approved for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
MS treatment trial to compare stem cell transplantation to biologic drugs
The BEAT-MS trial aims to compare the experimental autologous hematopoietic stem cell transplantation (AHSCT) therapy to the best available biologic therapies for multiple sclerosis (MS).
Taro Pharmaceuticals voluntarily recalls one lot of lamotrigine tablets
Due to cross-contamination with enalapril maleate, Taro is voluntarily recalling one lot of its lamotrigine tablets at the consumer level.
Eli Lilly to acquire biopharma company Dermira for $1.1bn
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
T-cell lymphomas treatment trial update announced by Innate Pharma
Enrolment of new patients in the TELLOMAK trial, which has been evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas, has been suspended.
Pharmaceutical packaging equipment market forecasted to reach $11.46bn by 2026
The pharmaceutical packaging equipment market is expected to reach a value of $11.46 billion due to market leader innovations and tightening packaging regulations, says report.
US study investigates how medicines can be removed from wastewater
New research has shown that technologies are available for US treatment plants to remove medicines from wastewater but that upgrades can be expensive.
FDA approves Ayvakit, the first targeted gastrointestinal stromal tumour treatment
The FDA has approved Ayvakit for the treatment of GISTs with platelet-derived growth factor receptor alpha mutations, following 84 percent response rate in clinical trials.
Half of US spending on brand medicines went to supply chain in 2018
A study has revealed that in 2018, almost half of the spending on brand medicines went to the supply chain and other entities in the US.
Governor of California proposes state-run drug label
In a bid to lower the costs of medicines, California's governor has suggested contracting generic drug manufacturers to make pharmaceutical products for the state to sell, according to reports.
FDA approves sNDA for candidiasis treatment in paediatric patients
Supplemental new drug application (sNDA) has been approved for an expanded indication of MYCAMINE® for the treatment of invasive candidiasis in paediatric patients under four months old.
Supply chain and drug pricing reform required to lower US healthcare costs
Price caps and government regulations will not lower US healthcare costs, instead supply chain and drug pricing reforms are required, says a brief by medical economist.
